Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67)

Diabetic Medicine

Volumn 22, Issue 3, 2005, Pages 306-311

  Adler, Amanda I ^a,b   Levy, J C ^a   Matthews, D R ^a   Stratton, I M ^a   Hines, G ^a   Holman, R R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular disease; Diabetes; Insulin resistance; Prospective

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR RISK; CORONARY RISK; CORRELATION FUNCTION; DISEASE ASSOCIATION; FEMALE; HEART INFARCTION; HUMAN; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; STROKE; UNITED KINGDOM;

ADULT; AGED; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK; WAIST-HIP RATIO;

EID: 14644390267     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2004.01418.x     Document Type: Article

References (41)

1. Reaven G. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
2. Trevisan M, Liu J, Bahsas F, Menotti A. Syndrome X and mortality: a population-based study. Risk Factor and Life Expectancy Research Group. Am J Epidemiol 1998; 148: 958-966.
3. Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Circulation 1998; 98: 398-104.
4. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12 year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444.
5. Turner R, Millns H, Neil H, Stratton I, Manley S, Matthews D et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). Br Med J 1998; 316: 823-828.
6. Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002; 25: 1135-1141.
7. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
8. UKPDS Group. UK Prospective Diabetes Study XI. Biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med 1994; 11: 534-544.
9. UKPDS Group. UK Prospective Diabetes Study VIII. Study design, progress and performance. Diabetologia 1991; 34: 877-890.
10. Levy J, Matthews D, Hermans M. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998; 21: 2191-2192.
11. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R. Homeostasis model assessment, insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-491.
12. Hermans M, Levy J, Morris R, Turner R. Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia 1999; 42: 678-687.
13. UKPDS Group. UK Prospective Diabetes Study 16 Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258.
14. UKPDS Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
15. Stevens R, Kothari V, Adler A, Sratton I, Holman R. The UKPDS Risk Engine: a model for the risk of coronary heart disease in type 2 diabetes (UKPDS 56). Clin Sci 2001; 101: 671-679.
16. Haffner S, Kennedy E, Gonzalez C, Stern M, Miettinen H. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care 1996; 19: 1138-1141.
17. Resnick H, Jones K, Ruotolo G, Jain A, Henderson J, Lu W et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care 2003; 26: 861-867.
18. Hanley A, Williams K, Stern M, Haffner S. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care 2002; 25: 1177-1184.
19. Adler A, Neil H, Manley S, Holman R, Turner R. for the UKPDS Study Group. Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom prospective diabetes study (UKPDS 47). Am Heart J 1998; 138: S353-359.
20. Howard G, O'Leary D, Zaccaro D, Haffner S, Rewers M, Hamman R et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 1996; 93: 1809-1817.
21. Levy J, Atkinson AB, Bell PM, McCance DR, Haddon DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 1998; 15: 290-296.
22. Ruige J, Assendelft W, Dekker J, Kostense P, Heine R, Bouter L. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation 1998; 97: 996-1001.
23. Shinohara K, Shoji T, Emoto M, Tahara H, Koyama H, Ishimura E et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 1894-1900.
24. Festa A, D'Agostino RJ, Howard G, Mykkanen L, Tracy R, Haffner S. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47.
25. Reaven G. The kidney: an unwilling accomplice in syndrome X. Am J Kidney Dis 1997; 30: 928-931.
26. Ikeda Y, Suehiro T, Nakamura T, Kumon Y, Hashimoto K. Clinical significance of the insulin resistance index as assessed by homeostasis model assessment. Endocr J 2001; 48: 81-86.
27. Kirwan J, Huston-Presley L, Kalhan S, Catalane P. Clinically useful estimates of insulin sensitivity during pregnancy: validation studies in women with normal glucose tolerance and gestational diabetes mellitus. Diabetes Care 2001; 24: 1602-1607.
28. McAuley K, Williams S, Mann J, Walker R, Lewis-Earned N, Temple L et al. Diagnosing insulin resistance in the general population. Diabetes Care 2001; 24: 460-464.
29. Katsuki A, Sumida Y, Gabazza E, Murashima S, Furuta M, Araki-Sasaki R et al. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care 2001; 24: 362-365.
30. Haffner S, Stern M, Mitchell B, Hazuda H, Patterson J. Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity, and body-fat distribution. Diabetes 1990; 39: 283-288.
31. Radziuk J. Insulin sensitivity and its measurement: Structural commonalities among the methods. J Clin Endocrinol Metabolism 2000; 85: 4426-4433.
32. Moller D. Insulin Resistance. Hoboken: Jossey-Bass, 1993.
33. Bergman RN, Ider YZ, Bowden CR, Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol 1979; 236: 667-677.
34. Hennekens C, Buring J. Epidemiology in Medicine. New York: Little, Brown and Company, 1987.
35. Bonora E, Targher G, Alberiche MGF, Calcaterra F, Lombardi S et al. Predictors of insulin sensitivity in Type 2 diabetes mellitus. Diabet Med 2002; 19: 535-542.
36. Plutzky J, Viberti G, Haffner S. Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. J Diabetes Complications 2002; 16: 401-415.
37. Zinman B. PPAR gamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone. Diabetes Obes Metab 2001; 3 (Suppl. 1): S34-43.
38. Hanefeld M. Pharmacokinetics and clinical efficacy of pioglitazone. Int J Clin Pract Suppl 2001; 121: 19-25.
39. Turner R, Millns H, Neil H, Stratton I, Manley S, Matthews D et al. UK Prospective Diabetes Study (UKPDS) 23: Risk factors for coronary artery disease in non-insulin dependent diabetes. BMJ 1997; 316: 823-828.
40. Boule N, Haddad E, Kenny G, Wells G, Sigal R. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA 2001; 12: 1218-1227.
41. Pirro M, Mauriege P, Tchernof A, Cantin B, Dagenais G, Despres J et al. Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Atherosclerosis 2002; 160: 377-384.